07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

5B1 antibody: Phase I started

MabVax began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate 3 mg IV MVT-2163 with or without 17 or 47 mg IV MVT-5873 in about 28 patients. MabVax’s MVT-2163 is a radiolabeled HuMab-5B1...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

MVT-2163: Phase I started

MabVax began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate 3 mg IV MVT-2163 with or without 17 or 47 mg IV MVT-5873 in about 28 patients. MabVax’s MVT-5873 is a human IgG1...